What I wrote before was obviously simplistic and considering only the RP11 treatment. It is likely that, if the 36 month path is chosen, the PKD treatment will beat it to the market. That would be great, but how to fund the PKD trial(s) if they want to keep the proceeds “in house”? Can they get a decent licensing deal for the RP11 with a big pharma company knowing there’s 36 months until they get a clear answer and can sell it? OR…another CR? OR license the CPP tech to someone who sees the potential for their application?
I don’t profess to have answers…just questions.
Ann: Q3 2024 Investor Webinar Presentation, page-11
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
-0.015(8.11%) |
Mkt cap ! $793.2M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.0¢ | $419.2K | 2.405M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 326555 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 222720 | 4 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PYC (ASX) Chart |